Technicals — Up 7.92% to $262.63, sitting 0.02% below the $262.68 52-week high — a breakout at new-high levels. Up 35.6% on the week and 42.4% on the month, price trades 28% above the 20-day ($205), 40% above the 50-day ($188) and 32% above the 200-day ($199), with all averages in fully bullish, widely fanned alignment. RSI(14) at 80.8 and RSI7 at 89.4 are extremely overbought — the position's main technical risk, since extreme overbought readings on a vertical advance raise the odds of a pullback materially. ATR of $11.4 is about 4.3% of spot. First support sits in the prior $230–240 breakout shelf, then the 20-day at $205.
Fundamentals — The Q2 print explains the entire move, and its quality is high: adjusted EPS of $6.12 crushed the $4.26 consensus (a 43.7% beat) on revenue of $5.63 billion versus $5.42 billion expected. More important was the guidance raise — full-year EPS lifted to $20.30–$21.69 against prior consensus of $17.81, with revenue guided to $21.9–22.5 billion. Same-facility growth of 5.0% indicates operational improvement (recovering volumes plus cost discipline) rather than a one-off. At 10.1x trailing earnings after a major upward revision, the valuation-versus-earnings mismatch is unusual.
News — The stock jumped more than 23% the session after earnings and has stayed strong. On July 28 healthcare became the market's shelter: XLV rose 2.36%, in sharp contrast to the Nasdaq's -0.63% and SOXX's -4.8%. The same day IQVIA beat and raised, rising 13.94% to lead the S&P 500. The pattern is clear — on the day the AI hardware narrative faltered, money moved systematically into reasonably valued healthcare services with dependable cash flow. Tenet benefits from both its own results and the sector beta.
Continue holding (maintaining long), explicitly without adding. Fundamentals fully support the position: a 43.7% EPS beat, full-year guidance raised by nearly three dollars, 5.0% same-facility growth and 10.1x earnings still undemanding post-revision. But RSI7 at 89.4 is extremely overbought, price is 0.02% from the 52-week high and just 5.5% from the $277 consensus target, so near-term risk/reward has turned asymmetric. The stop moves up to $236, near the top of the prior $230–240 breakout shelf (about 2.3 ATR below spot), locking in most of the move while allowing room to breathe. The $277 target matches consensus. A pullback into $240–248 — between the 20-day and the breakout shelf — would be the rational place to add.
Long-term value for hospital operators comes from recovering volumes plus cost leverage, and Tenet's 5.0% same-facility growth and sharply raised guidance show both paths delivering. At 10.1x, a healthcare services company with steadily improving profitability and a strengthening credit profile still looks undervalued. Inelastic demand for care gives the sector defensive characteristics amid macro uncertainty and swings in the AI capex cycle, making it a sensible hedge against technology concentration in a portfolio.
- RSI7 at 89.4 is extremely overbought; near-term pullback risk is high
- Only 5.5% from consensus targets — upside is largely priced in
- Reimbursement policy and rate changes affect profitability
- A renewed rise in labor costs, especially nursing wages, would erode margins
- StockTwits · Semis bled and hospital stocks made new highs. The market never runs out of money — it just changes where the money sleepsOriginal ↗
- 华尔街共识 · 25 analysts average a $277.10 target, only 5.5% above the $262.63 spot, with a 1.24 rating near Strong Buy — the rally has compressed the upside to targets, signalling the move is well advanced
- Yahoo Finance · Reported a Q2 beat on both results and guidance, with 5.0% same-facility growth and cost control driving margin improvementSource ↗